• 1
    Grem JL. Fluoropyrimidines. In: ChabnerBA, CollinsJM, editors. Pharmacologic principles of cancer treatment. 2nd ed. Philadelphia: WB Saunders, 1990: 180224.
  • 2
    Grem JL, Hoth D, Hamilton MJ, King SA, Leyland-jones B. An overview of the current status and future directions of clinical trials of 5-fluorouracil and folinic acid. Cancer Treat Rep 1987; 71: 124964.
  • 3
    The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncoh 1992; 10: 896903.
  • 4
    Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 42532.
  • 5
    Hansen R, Ryan L, Anderson T, Quebbeman E, Haller D. A Phase III trial of bolus 5-FU versus protracted infusion 5FU cisplatin in metastatic colorectal cancer: an Eastern Cooperative Oncology Group study (EST 2286) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 154.
  • 6
    Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 89235.
  • 7
    Newman E, Straw JA, Doroshow JH. Pharmacokinetics of diastereoisomers of (6 R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 1989; 49: 575560.
  • 8
    Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, et al. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 181120.
  • 9
    Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 10
    Hansen RM. 5-fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 1991; 9: 63742.
  • 11
    Jeske J, Hansen RM, Libnoch JA, Anderson T. 5-Fluorouracil infusion and low-dose weekly cisplatin: an analysis of increased toxicity. Am J Clin Oncol 1990; 13: 48588.
  • 12
    Lokich JJ, Ahlgren JD, Cantrell J, Heim WJ, Wampler GL, Gullo JJ, et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer 1991; 67: 149.
  • 13
    Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988; 48: 45961.
  • 14
    Harris BE, Song R, Soong S-J, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197201.
  • 15
    Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986; 16: 646.
  • 16
    Erlichman C, Fine S, Elhakim T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 1986; 70: 9034.
  • 17
    Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, et al. Phase I trial of 5-fluorouracil and dipyridamole administered by 72 hour concurrent continuous infusion. Cancer Res 1990; 50: 266772.
  • 18
    Grem J, McAtee N, Murphy R, Balis F, Drake J, Hamilton J, et al. Phase I study of continuous IV infusion 5-FU and leucovorin plus N-(phosphonacetyl)-L-aspartate in advanced GI cancer [abstract]. Proc Am Soc Clin Oncol 1992; 11: 112.
  • 19
    Lee GR. Megaloblastic and nonmegaloblastic macrocytic anemias. In: LeeGR, BithellTC, FoersterJ, AthensJW, LukensJN, editors. Wintrobe's clinical hematology. 9th ed. Philadelphia: Lea & Febiger, 1993: 7701.
  • 20
    Brennan MJ, Waitkevicius VK, Rebuck JW. Megaloblastic anemia associated with inhibition of thymine synthesis (observations during 5-fluorouracil treatment). Blood J 1960; 14: 153545.
  • 21
    Wickramansinghe SN, Saunder JE. Results of 3 years' experience with the deoxyuridine suppression test. Acta Hematol 1977; 58: 193206.
  • 22
    Leichman LP, Leichman CG, Kinzie J. Biochemical modification of protracted infusion 5-fluorouracil with weekly leucovorin: a dose-seeking clinical trial for patients with disseminated gastrointestinal cancers. Cancer Chemother Pharmacol 1990; 26: 5761.